편두통 치료제 시장 : 치료제별, 투여 경로별, 지역별(2025-2032년)

Migraine Therapeutic Market is estimated to be valued at USD 6,850.9 Mn in 2025 and is expected to reach USD 12,931.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There's no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.

Market Dynamics

Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2020, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Key features of the study

• This report provides in-depth analysis of the global migraine therapeutic market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.

Market Segmentation

• Global Migraine Therapeutic Market, By Therapeutics
  • Pain-relieving Medications
  • Preventive Medications
• Global Migraine Therapeutic Market, By Route of Administration
  • Oral and Nasal
  • Injection
• Global Migraine Therapeutic Market, By Geography
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Allergan Inc.
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapeutics
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increase in prevalence of migraine around the world
  • Adverse effects of drugs and increasing undiagnosed cases
  • Increase in demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Migraine Therapeutic Market, By Therapeutics, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pain-relieving Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Preventive Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Migraine Therapeutic Market, By Route of Administration, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral and Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Migraine Therapeutic Market, By Geography, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• South Africa
• North Africa
• Central Africa

7. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Allergan Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us